Release issued 3rd September 2004

August 30, 2004--Waltham, Mass.--Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that the overall dermatology drug market (which includes atopic dermatitis, urticaria, and psoriasis) will experience modest growth of 8% per year through 2008. According to the new DR Pipeline Report entitled Dermatology Pipeline Analysis: A Market with Room to Grow, the psoriasis market will experience the most growth, with the atopic dermatitis market seeing more modest growth. The urticaria market will actually experience a decline.

The report also finds that Amgen will become a significant emerging player in the dermatological drug market with Enbrel for the treatment of adults with moderate-to-severe chronic plaque psoriasis.

"Prior to 2004, Amgen did not compete in the dermatology market segment. However, in April of this year, the FDA approved the company's application for the extended use of its existing blockbuster product, Enbrel. The FDA approved Enbrel for extended use in the treatment of adults with moderate-to-severe chronic plaque psoriasis, enabling Amgen to enter the dermatology market", said Heather Martin, analyst at Decision Resources. "By 2008, as a result of this approval, Enbrel should gain the third-highest market share in the dermatology indications of psoriasis, atopic dermatitis and urticaria."

The overall dermatological disease market constitutes the ninth-largest segment of the global pharmaceutical market.

The full release will be on the web site shortly. www.decisionresources.com

(30th October 2009) Patient-targeted messaging for Emerging Multiple Sclerosis agents needs to highlight efficacy and preservation of quality of life

(26th October 2009) Continued uptake of Tnf-Alpha Inhibitors and Interleukin Inhibitors will drive US $2.2 billion growth in the Psoriasis drug market

(22nd October 2009) Tnf-Alpha Inhibitors will continue to dominate first- and second-line Biologic Therapy for the treatment of Rheumatoid Arthritis through 2011

(21st October 2009) Majority of surveyed physicians prescribe Cymbalta and Lyrica for treatment of Fibromyalgia but neither agent has the majority of its uses in first line

(15th October 2009) Sales of Glaxosmithkline’s Relenza likely to increase during the A/H1N1 2009 pandemic as Tamiflu-Resistant Strains of the virus spread